Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing

Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

Measles Map Shows States Where 2026 Cases Already Surpass 2025

In 2000, the United States declared that measles was eliminated, in large part, due to the MMR vaccine.

  • Pennsylvania reports first measles death in 2026, raising concerns
  • 2026 marks highest U.S. measles case count since 1991 with 3,300+
  • CDC Epi-Aid support requested by Texas, SC, VA, KS, NM, WI, but not PA

More from Monday 14 September →